SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-21-012043
Filing Date
2021-05-13
Accepted
2021-05-13 16:01:47
Documents
69
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20210331_10q.htm 10-Q 779703
2 EXHIBIT 31.1 ex_247768.htm EX-31.1 8719
3 EXHIBIT 32.1 ex_247769.htm EX-32.1 4665
  Complete submission text file 0001437749-21-012043.txt   5153134

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT navb-20210331.xml EX-101.INS 860765
5 XBRL TAXONOMY EXTENSION SCHEMA navb-20210331.xsd EX-101.SCH 57119
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20210331_cal.xml EX-101.CAL 37747
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20210331_def.xml EX-101.DEF 491501
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20210331_lab.xml EX-101.LAB 342319
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20210331_pre.xml EX-101.PRE 505438
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 21919482
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences